Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

NCT00102323 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00102323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2005
Completion date
March 1, 2007
Enrollment
63 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura, thrombocytopenia